Stephens Inc. AR Sells 8,678 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Stephens Inc. AR lowered its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 36.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 15,095 shares of the company’s stock after selling 8,678 shares during the quarter. Stephens Inc. AR’s holdings in Castle Biosciences were worth $431,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of CSTL. US Bancorp DE raised its holdings in shares of Castle Biosciences by 1,889.2% in the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after purchasing an additional 4,383 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after purchasing an additional 2,093 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Castle Biosciences by 10.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares during the period. XTX Topco Ltd bought a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $218,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Castle Biosciences by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after purchasing an additional 675 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Robert W. Baird lifted their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday. Scotiabank boosted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a report on Wednesday. Lake Street Capital boosted their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. KeyCorp boosted their target price on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Stephens reissued an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $37.88.

Castle Biosciences Stock Up 4.8 %

Shares of NASDAQ:CSTL opened at $32.66 on Thursday. Castle Biosciences, Inc. has a 52-week low of $16.20 and a 52-week high of $35.84. The firm has a fifty day moving average of $30.78 and a 200 day moving average of $25.72. The firm has a market capitalization of $901.64 million, a PE ratio of 163.30 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same period in the previous year, the business earned ($0.26) earnings per share. As a group, research analysts anticipate that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 986 shares of the business’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the sale, the insider now directly owns 94,622 shares of the company’s stock, valued at $2,718,490.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.44, for a total value of $231,604.48. Following the completion of the sale, the director now directly owns 5,700 shares of the company’s stock, valued at $167,808. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the business’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $28.73, for a total transaction of $28,327.78. Following the completion of the sale, the insider now directly owns 94,622 shares of the company’s stock, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,694 shares of company stock valued at $563,497 over the last three months. Insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.